Modality
Nanobody
MOA
Menini
Target
Tau
Pathway
Tau
CeliacUCMyelofibrosis
Development Pipeline
Preclinical
~Aug 2021
→ ~Nov 2022
Phase 1
~Feb 2023
→ ~May 2024
Phase 2
Aug 2024
→ Jun 2026
Phase 2Current
NCT03848552
495 pts·Myelofibrosis
2024-08→2026-06·Recruiting
495 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-06-062mo awayPh2 Data· Myelofibrosis
Trial Timeline
Q42025Q2Q3Q42026Q2
P2
Recruit…
Catalysts
Ph2 Data
2026-06-06 · 2mo away
Myelofibrosis
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03848552 | Phase 2 | Myelofibrosis | Recruiting | 495 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Olpafutibatinib | Immunocore | Approved | SMN2 | |
| TER-5062 | Terns | Phase 2/3 | Tau | |
| TXG-6755 | 10x Genomics | Approved | CD123 | |
| Zoricapivasertib | CSL Limited | Phase 2 | HER2 |